Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript

Page 6 of 6

But we’ll also be backing that up with our legacy system, our legacy solutions in positive blood cultures as well. So it will be an integrated platform. We’re looking at preclinical readouts at the end of the year in Q4. We’re looking at starting clinical trials sometime thereafter. And again, it will be an exciting leap forward for Accelerate as we continue to move the needle in this space. So with that, I’ll bring this call to a close. As I mentioned in my remarks, if you would like a further dialogue or have questions, please go to the website and request a meeting or ask those questions, and David and I will certainly respond in a short, short order. So thank you very much, and I hope everyone has a great day. Bye-bye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.

Follow Accelerate Diagnostics Inc (NASDAQ:AXDX)

Page 6 of 6